About Us

Leading the way
in immunotherapy

About
us

Leading the way
in immunotherapy

Who We Are

Cytovation builds on over 15 years of cutting-edge research from two leading Norwegian institutions; University of Bergen and Haukeland University Hospital.

Led by a highly experienced management team and world-renowned experts in tumor biology, an extensive research program has focused on engineering synthetic peptides with unique, antitumoral properties.

CyPep-1, the company’s lead candidate, is being developed as a first-in-class tumor membrane targeting agent for the treatment of solid tumors.

Management

CEO

Lars Prestegarden

CBO/CFO

Federico Grego

Chief Development Officer

Iman Barilero

Head of Clinical Development

Cesar Pico

Director

Raj Airey

Vice President of Operations

Helén Johansen Blanco

Clinical Project Manager

Jeanette Kamman

Lead CRA

Sandra Jansen

Deputy CFO

Vetle Veiteberg

Advisors

Rolf Bjerkvig

Ole-Erik Iversen

Bo Jesper Hansen

Xavier Luria

Board

Chairman

Stein-Christian Mohn

Board Member

Liv H. Dyrnes

Board Member

Olav Hellebø

Board Member

Øyvind Kongstun Arnesen

Board Member

Hilde Hukkelberg